Risk of Heart Failure Up for Rheumatoid Arthritis Patients

Share this content:
Risk of Heart Failure Up for Rheumatoid Arthritis Patients
Risk of Heart Failure Up for Rheumatoid Arthritis Patients

TUESDAY, March 14, 2017 (HealthDay News) -- Patients with rheumatoid arthritis (RA) have increased risk of heart failure, according to a study published in the March 14 issue of the Journal of the American College of Cardiology.

Ängla Mantel, M.D., from the Karolinska Institutet in Stockholm, and colleagues identified two contemporary cohorts of RA subjects from Swedish patient and rheumatology registries and matched them 1:10 to comparator subjects from the general population. The authors assessed first-ever heart failure diagnosis through registry linkages.

The researchers found that a history of heart failure was not more common in RA by the time of RA onset. The overall hazard ratios for subsequent heart failure (any type), ischemic heart failure, and non-ischemic heart failure were between 1.22 and 1.27 among new-onset RA patients. There was a rapid increase in the risk of non-ischemic heart failure after onset of RA, in contrast to the risk of ischemic heart failure. There were correlations for high disease activity with all heart failure types, with the most pronounced correlation for non-ischemic heart failure. For the different heart failure subtypes, the hazard ratios were between 1.71 and 1.88 in the cohort of patients with RA of any duration.

"Patients with RA are at increased risk of heart failure that cannot be explained by their increased risk of ischemic heart disease," the authors write. "The increased risk of non-ischemic heart failure occurred early and was associated with RA severity."

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »